var data={"title":"Treatment protocols for gynecologic malignancies","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for gynecologic malignancies</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-gynecologic-malignancies/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H15357686\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of women with gynecologic cancers. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with gynecologic cancers. Additional regimens may be added over time, particularly as treatment for gynecologic cancers evolve. </p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with gynecologic cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"headingAnchor\" id=\"H15357842\"><span class=\"h2\">Ovarian cancer</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer\" class=\"medical medical_review\">&quot;First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer\" class=\"medical medical_review\">&quot;Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-sensitive-disease\" class=\"medical medical_review\">&quot;Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-resistant-disease\" class=\"medical medical_review\">&quot;Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15358532\"><span class=\"h2\">Endometrial cancer</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=approach-to-adjuvant-treatment-of-endometrial-cancer\" class=\"medical medical_review\">&quot;Approach to adjuvant treatment of endometrial cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-treatment-of-high-risk-endometrial-cancers\" class=\"medical medical_review\">&quot;Adjuvant treatment of high-risk endometrial cancers&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-recurrent-or-metastatic-endometrial-cancer\" class=\"medical medical_review\">&quot;Treatment of recurrent or metastatic endometrial cancer&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15359201\"><span class=\"h2\">Cervical cancer</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-locally-advanced-cervical-cancer\" class=\"medical medical_review\">&quot;Management of locally advanced cervical cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-recurrent-or-metastatic-cervical-cancer\" class=\"medical medical_review\">&quot;Management of recurrent or metastatic cervical cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=small-cell-neuroendocrine-carcinoma-of-the-cervix#H1336437742\" class=\"medical medical_review\">&quot;Small cell neuroendocrine carcinoma of the cervix&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=invasive-cervical-adenocarcinoma\" class=\"medical medical_review\">&quot;Invasive cervical adenocarcinoma&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15359490\"><span class=\"h2\">Uterine sarcoma</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-diagnosis-staging-and-treatment-of-uterine-carcinosarcoma\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-and-prognosis-of-uterine-leiomyosarcoma\" class=\"medical medical_review\">&quot;Treatment and prognosis of uterine leiomyosarcoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=classification-and-treatment-of-endometrial-stromal-sarcoma-and-uterine-adenosarcoma\" class=\"medical medical_review\">&quot;Classification and treatment of endometrial stromal sarcoma and uterine adenosarcoma&quot;</a>.)</p><p/><p>In addition, protocols for the treatment of women with sex cord stromal and germ cell tumors are covered separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-protocols-for-germ-cell-tumors\" class=\"medical medical_review\">&quot;Treatment protocols for germ cell tumors&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H15359315\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H15359323\"><span class=\"h2\">Regimens for ovarian cancer</span></p><p class=\"headingAnchor\" id=\"H15359348\"><span class=\"h3\">Cisplatin plus paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50698\" class=\"graphic graphic_table graphicRef50698 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H15359396\"><span class=\"h3\">Carboplatin plus paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=OBGYN%2F65626\" class=\"graphic graphic_table graphicRef65626 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H1067422739\"><span class=\"h3\">Carboplatin plus pegylated liposomal doxorubicin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86168\" class=\"graphic graphic_table graphicRef86168 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H15359437\"><span class=\"h3\">GOG 172 regimen (intravenous (IV) paclitaxel followed by intraperitoneal (IP) cisplatin and IP paclitaxel)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=OBGYN%2F61475\" class=\"graphic graphic_table graphicRef61475 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H1650215328\"><span class=\"h3\">Weekly paclitaxel with every three week carboplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87790\" class=\"graphic graphic_table graphicRef87790 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H1734336749\"><span class=\"h3\">Carboplatin and gemcitabine plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87827\" class=\"graphic graphic_table graphicRef87827 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H15359558\"><span class=\"h2\">Regimens for endometrial cancer</span></p><p class=\"headingAnchor\" id=\"H15359597\"><span class=\"h3\">Carboplatin plus paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=OBGYN%2F65626\" class=\"graphic graphic_table graphicRef65626 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H15359621\"><span class=\"h2\">Regimens for cervical cancer</span></p><p class=\"headingAnchor\" id=\"H934171843\"><span class=\"h3\">EP (etoposide plus cisplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F63222\" class=\"graphic graphic_table graphicRef63222 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H15359662\"><span class=\"h3\">Cisplatin plus paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50698\" class=\"graphic graphic_table graphicRef50698 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H15359703\"><span class=\"h3\">Carboplatin plus paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=OBGYN%2F65626\" class=\"graphic graphic_table graphicRef65626 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H15359727\"><span class=\"h2\">Regimens for uterine sarcoma</span></p><p class=\"headingAnchor\" id=\"H1535941416\"><span class=\"h3\">Gemcitabine plus docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F58713\" class=\"graphic graphic_table graphicRef58713 \">table 8</a>) </p><p class=\"headingAnchor\" id=\"H4107285581\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-cervical-cancer\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Cervical cancer&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85681 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H15357686\" id=\"outline-link-H15357686\">INTRODUCTION</a><ul><li><a href=\"#H15357842\" id=\"outline-link-H15357842\">Ovarian cancer</a></li><li><a href=\"#H15358532\" id=\"outline-link-H15358532\">Endometrial cancer</a></li><li><a href=\"#H15359201\" id=\"outline-link-H15359201\">Cervical cancer</a></li><li><a href=\"#H15359490\" id=\"outline-link-H15359490\">Uterine sarcoma</a></li></ul></li><li><a href=\"#H15359315\" id=\"outline-link-H15359315\">REGIMENS</a><ul><li><a href=\"#H15359323\" id=\"outline-link-H15359323\">Regimens for ovarian cancer</a><ul><li><a href=\"#H15359348\" id=\"outline-link-H15359348\">- Cisplatin plus paclitaxel</a></li><li><a href=\"#H15359396\" id=\"outline-link-H15359396\">- Carboplatin plus paclitaxel</a></li><li><a href=\"#H1067422739\" id=\"outline-link-H1067422739\">- Carboplatin plus pegylated liposomal doxorubicin</a></li><li><a href=\"#H15359437\" id=\"outline-link-H15359437\">- GOG 172 regimen (intravenous (IV) paclitaxel followed by intraperitoneal (IP) cisplatin and IP paclitaxel)</a></li><li><a href=\"#H1650215328\" id=\"outline-link-H1650215328\">- Weekly paclitaxel with every three week carboplatin</a></li><li><a href=\"#H1734336749\" id=\"outline-link-H1734336749\">- Carboplatin and gemcitabine plus bevacizumab</a></li></ul></li><li><a href=\"#H15359558\" id=\"outline-link-H15359558\">Regimens for endometrial cancer</a><ul><li><a href=\"#H15359597\" id=\"outline-link-H15359597\">- Carboplatin plus paclitaxel</a></li></ul></li><li><a href=\"#H15359621\" id=\"outline-link-H15359621\">Regimens for cervical cancer</a><ul><li><a href=\"#H934171843\" id=\"outline-link-H934171843\">- EP (etoposide plus cisplatin)</a></li><li><a href=\"#H15359662\" id=\"outline-link-H15359662\">- Cisplatin plus paclitaxel</a></li><li><a href=\"#H15359703\" id=\"outline-link-H15359703\">- Carboplatin plus paclitaxel</a></li></ul></li><li><a href=\"#H15359727\" id=\"outline-link-H15359727\">Regimens for uterine sarcoma</a><ul><li><a href=\"#H1535941416\" id=\"outline-link-H1535941416\">- Gemcitabine plus docetaxel</a></li></ul></li></ul></li><li><a href=\"#H4107285581\" id=\"outline-link-H4107285581\">SOCIETY GUIDELINE LINKS</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85681|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/50698\" class=\"graphic graphic_table\">- Cisplatin and paclitaxel for SCC of cervix</a></li><li><a href=\"image.htm?imageKey=OBGYN/65626\" class=\"graphic graphic_table\">- Paclitaxel and carboplatin chemotherapy for EOC</a></li><li><a href=\"image.htm?imageKey=ONC/86168\" class=\"graphic graphic_table\">- Pegylated liposomal doxorubicin and carboplatin EOC</a></li><li><a href=\"image.htm?imageKey=OBGYN/61475\" class=\"graphic graphic_table\">- Paclitaxel-cisplatin-paclitaxel for epithelial ovarian cancer</a></li><li><a href=\"image.htm?imageKey=ONC/87790\" class=\"graphic graphic_table\">- Paclitaxel carboplatin ovarian</a></li><li><a href=\"image.htm?imageKey=ONC/87827\" class=\"graphic graphic_table\">- OCEANS gyn protocol</a></li><li><a href=\"image.htm?imageKey=ONC/63222\" class=\"graphic graphic_table\">- Cisplatin and etoposide for relapsed germ cell tumors</a></li><li><a href=\"image.htm?imageKey=ONC/58713\" class=\"graphic graphic_table\">- Gem plus doc for advanced sarcoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer\" class=\"medical medical_review\">Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-treatment-of-high-risk-endometrial-cancers\" class=\"medical medical_review\">Adjuvant treatment of high-risk endometrial cancers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-adjuvant-treatment-of-endometrial-cancer\" class=\"medical medical_review\">Approach to adjuvant treatment of endometrial cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-and-treatment-of-endometrial-stromal-sarcoma-and-uterine-adenosarcoma\" class=\"medical medical_review\">Classification and treatment of endometrial stromal sarcoma and uterine adenosarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-staging-and-treatment-of-uterine-carcinosarcoma\" class=\"medical medical_review\">Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer\" class=\"medical medical_review\">First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-cervical-adenocarcinoma\" class=\"medical medical_review\">Invasive cervical adenocarcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-locally-advanced-cervical-cancer\" class=\"medical medical_review\">Management of locally advanced cervical cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-recurrent-or-metastatic-cervical-cancer\" class=\"medical medical_review\">Management of recurrent or metastatic cervical cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-resistant-disease\" class=\"medical medical_review\">Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-sensitive-disease\" class=\"medical medical_review\">Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=small-cell-neuroendocrine-carcinoma-of-the-cervix\" class=\"medical medical_review\">Small cell neuroendocrine carcinoma of the cervix</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-cervical-cancer\" class=\"medical medical_society_guidelines\">Society guideline links: Cervical cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-uterine-leiomyosarcoma\" class=\"medical medical_review\">Treatment and prognosis of uterine leiomyosarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-recurrent-or-metastatic-endometrial-cancer\" class=\"medical medical_review\">Treatment of recurrent or metastatic endometrial cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-protocols-for-germ-cell-tumors\" class=\"medical medical_review\">Treatment protocols for germ cell tumors</a></li></ul></div></div>","javascript":null}